Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy

Area of Science:

• Oncology
• Cancer Biology
• Medicinal Chemistry

Background:

• Platinum-based chemotherapy is a cornerstone for treating solid tumors, acting via DNA damage.
• Cancer cells utilize DNA damage response (DDR) pathways to resist chemotherapy.
• Targeting DDR pathways presents a strategy to overcome treatment resistance.

Purpose of the Study:

• To review preclinical and clinical findings on platinum and ruthenium anticancer complexes combined with PARP inhibitors.
• To explore the potential of ruthenium and gold complexes as direct PARP inhibitors.

Main Methods:

• Literature review of early-stage, preclinical, and clinical studies.
• Analysis of combination therapies involving DNA-binding metal complexes and DDR inhibitors.
• Examination of emerging research on metal complexes targeting PARP activity.

Main Results:

• Platinum and ruthenium complexes show synergistic effects with PARP inhibitors in preclinical and clinical settings.
• Emerging ruthenium and gold complexes demonstrate direct inhibition of PARP activity.
• Combination strategies aim to exploit cancer's reliance on DNA repair.

Conclusions:

• Combining platinum and ruthenium anticancer agents with PARP inhibitors is a promising strategy for enhanced cancer cell killing.
• Ruthenium and gold complexes offer novel avenues for direct PARP inhibition, potentially improving combination therapies.